Spore.Bio develops an ultra-fast, AI-based microbiology testing technology designed for manufacturing quality control in industries such as food and beverage, cosmetics, pharmaceuticals, and cell and gene therapies. The company's proprietary platform, known as Transformer-based Multimodal Spectral Imaging (TMSI), provides a direct method to detect, quantify, and identify living micro-organisms without requiring culture, enrichment, or dye.

By combining photonics, advanced machine learning models, and chemometrics, the technology takes optical snapshots of samples and recognizes the specific spectral signatures of bacteria, yeasts, and molds in minutes rather than days. This enables factories to perform on-site, real-time testing, helping companies prevent costly product recalls, reduce contamination risks, and maintain regulatory compliance.

Founded in Paris in 2023, Spore.Bio has established academic partnerships, including with the Pasteur Institute, and serves industrial clients globally across multiple manufacturing sectors.